Literature DB >> 27810515

Mortality in Dravet syndrome.

Monica S Cooper1, Anne Mcintosh2, Douglas E Crompton3, Jacinta M McMahon4, Amy Schneider4, Kevin Farrell5, Vijeya Ganesan6, Deepak Gill7, Sara Kivity8, Tally Lerman-Sagie9, Ailsa McLellan10, James Pelekanos11, Venkateswaran Ramesh12, Lynette Sadleir13, Elaine Wirrell14, Ingrid E Scheffer15.   

Abstract

We measured the mortality rate and the rate of Sudden Unexpected Death in Epilepsy (SUDEP) in Dravet Syndrome (DS). We studied a cohort of 100 consecutively recruited, unrelated patients with DS; 87 had SCN1A mutations. Living cases had a median follow-up of 17 years. Seventeen patients died, at a median age of seven years (inter-quartile range 3-11 years) with causes of death: 10 SUDEP, four status epilepticus, two drowning and one asphyxia. The SUDEP classification included three Definite, one Definite Plus and six Probable. The Dravet-specific mortality rate/1000-person-years was 15.84 (98% CI 9.01-27.85). The Dravet-specific SUDEP rate was 9.32/1000-person-years (98% CI 4.46-19.45). The Dravet-specific SUDEP rate is the only documented syndrome-specific SUDEP rate. SUDEP in DS occurs mainly in childhood. It is also the highest SUDEP rate, considerably higher than the recent 5.1 SUDEP rate/1000-person-years for adults with refractory epilepsy. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dravet syndrome; Epilepsy; Mortality; Sudden unexpected death in epilepsy

Mesh:

Substances:

Year:  2016        PMID: 27810515     DOI: 10.1016/j.eplepsyres.2016.10.006

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  62 in total

1.  The Genetic Landscape of Epilepsy of Infancy with Migrating Focal Seizures.

Authors:  Rosemary Burgess; Shuyu Wang; Amy McTague; Katja E Boysen; Xiaoling Yang; Qi Zeng; Kenneth A Myers; Anne Rochtus; Marina Trivisano; Deepak Gill; Lynette G Sadleir; Nicola Specchio; Renzo Guerrini; Carla Marini; Yue-Hua Zhang; Heather C Mefford; Manju A Kurian; Annapurna H Poduri; Ingrid E Scheffer
Journal:  Ann Neurol       Date:  2019-12       Impact factor: 10.422

Review 2.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

Authors:  Heather E Olson; Scott T Demarest; Elia M Pestana-Knight; Lindsay C Swanson; Sumaiya Iqbal; Dennis Lal; Helen Leonard; J Helen Cross; Orrin Devinsky; Tim A Benke
Journal:  Pediatr Neurol       Date:  2019-02-23       Impact factor: 3.372

3.  Early-onset genetic epilepsies reaching adult clinics.

Authors:  David Lewis-Smith; Colin A Ellis; Ingo Helbig; Rhys H Thomas
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

Review 4.  [Sudden unexpected death in epilepsy (SUDEP) : Epidemiology, cardiac and other risk factors].

Authors:  Theodor W May; Carsten W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2019-09

5.  Interneuron Desynchronization Precedes Seizures in a Mouse Model of Dravet Syndrome.

Authors:  Conny H Tran; Michael Vaiana; Johan Nakuci; Ala Somarowthu; Kevin M Goff; Nitsan Goldstein; Priya Murthy; Sarah F Muldoon; Ethan M Goldberg
Journal:  J Neurosci       Date:  2020-02-26       Impact factor: 6.167

Review 6.  Review: The past, present and future challenges in epilepsy-related and sudden deaths and biobanking.

Authors:  M Thom; M Boldrini; E Bundock; M N Sheppard; O Devinsky
Journal:  Neuropathol Appl Neurobiol       Date:  2018-02       Impact factor: 8.090

Review 7.  Treatment Strategies for Dravet Syndrome.

Authors:  Kelly G Knupp; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 8.  Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

Authors:  Julie Ziobro; Krista Eschbach; Joseph E Sullivan; Kelly G Knupp
Journal:  Curr Treat Options Neurol       Date:  2018-10-13       Impact factor: 3.598

Review 9.  Recent Advances in the Drug Treatment of Dravet Syndrome.

Authors:  Elaine C Wirrell; Rima Nabbout
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

10.  Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.

Authors:  Jesse Elliott; Bláthnaid McCoy; Tammy Clifford; George A Wells; Doug Coyle
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.